MYLUNG Consortium Part 3: Observational Study

Launched by US ONCOLOGY RESEARCH · May 30, 2023

Keywords

ClinConnect Summary

**Summary of the MYLUNG Consortium Part 3 Trial**

The MYLUNG Consortium Part 3 trial is an important study that aims to understand how patients with non-small cell lung cancer (NSCLC) can benefit from biomarker-guided therapy. This means the study is looking at how different tests can help doctors choose the best treatment for patients based on their specific cancer characteristics. It includes both early stage and advanced stage patients who have not yet started treatment, allowing researchers to gather valuable information about how long it takes to get tested, any challenges along the way, and the overall results of these therapies.

To participate in this study, you need to be an adult (18 years or older) who has been newly diagnosed with early stage, locally advanced, or metastatic (spread) non-small cell lung cancer, and your doctor believes you are eligible for systemic therapy (a type of treatment that works throughout the body). Even if you have had earlier treatments but your cancer has come back after a year, you might still qualify. If you decide to join, you will need to sign a consent form, and enrollment should happen within 30 days of starting your treatment. The trial is currently recruiting participants, and anyone interested should talk to their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
• • Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment.
• • Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
• • Subjects must be enrolled within 30 days of initiation of systemic therapy
• • Signed informed consent
• Exclusion Criteria:
• • Stage IA at the time of enrollment
• • Subjects with small cell lung cancer
• • Subjects with Unknown primary tumor origin